Clinical presentation of tuberculosis: a nine-year single-center experience

Year 2018, Volume: 4 Issue: 3, 211 - 214, 04.07.2018

Ahmet Cemal Pazarlı , Timur Ekiz , Mehmet Akif Abakay

https://doi.org/10.18621/eurj.346654

Cited By: 2

Abstract

Objective. The aim of this study was to
determine the clinical presentation of tuberculosis cases from our center for
the last nine years. Methods. This study was set as
descriptive and retrospective. The data was obtained from the hospital records.
Subjects who had been diagnosed as tuberculosis and received treatment in our
center between the years 2007 and 2015 were included. The cases were classified
as newly diagnosed, relapse, transferred, and returning after default. Results.
There were 276 (171 males and 105 females) patients
with a mean age of 41.5 ± 19.2 years. Pulmonary involvement is the most
common presentation and seen in 155 (56.2%) patients. Lymph node and pleura are
the most common extrapulmonary involvements those are seen in 53 (19.2%) and 23
(8.3%) patients, respectively. Number of the cases seems to decreased after
2012.  Most (85.1%) of the patients were
newly diagnosed. Among the subjects, 55.2% of them had bacteriologic diagnosis,
35.1% had histopathologic diagnosis. Two subjects died during the treatment
period whereas 274 of them completed the treatment program. Conclusions.
Our results show that tuberculosis is seen mainly in the adult age group. While
pulmonary involvement is the most common presentation, lymph node and pleura
involvements are the most common extrapulmonary presentations. Number of the
tuberculosis seems to decrease for the recent years. Strict preventive measures
and treatment strategies should be administered. 

Keywords

Tuberculosis, pulmonary involvement, Mycobacterium tuberculosis, extrathoracic tuberculosis, lymphadenitis, treatment strategy

References

• [1] Sia IG, Wieland ML. Current Concepts in the Management of Tuberculosis. Mayo Clin Proc 2011;86:348-61.
• [2] Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010;375:1814-29.
• [3] Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015;46:1563-76.
• [4] Lönnroth K, Migliori GB, Raviglione M. Toward tuberculosis elimination in low-incidence countries: reflections from a global consultation. Ann Intern Med 2014;161:670-1.
• [5] Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 2012;10:407-16.
• [6] Coskun O, Safaz I, Gul CH, Ozgul A, Eyigun CP. Heterotopic ossification in a patient with tuberculous meningoencephalitis. Intern Med 2008;47:2195-6.
• [7] World Health Organization. Global Tuberculosis Control: Epidemiology, Strategy, Financing: WHO Report 2009. Geneva, Switzerland: World Health Organization; 2009.
• [8] Liao JR, Zhang D, Wu XL. Pulmonary tuberculosis combined with hepatic tuberculosis: a case report and literature review. Clin Respir J 2015;9:501-5.
• [9] Pefura-Yone EW, Kuaban C, Assamba-Mpom SA, Moifo B, Kengne AP. Derivation, validation and comparative performance of a simplified chest X-ray score for assessing the severity and outcome of pulmonary tuberculosis. Clin Respir J 2015;9:157-64.
• [10] Christopoulos A, Saif MW, Sarris EG, Syrigos KN. Epidemiology of active tuberculosis in lung cancer patients: a systematic review. Clin Respir J 2014;8:375-81.
• [11] Flor de Lima B, Tavares M. Risk factors for extensively drug-resistant tuberculosis: a review. Clin Respir J 2014;8:11-23.
• [12] Hassan WA, Darwish AM. Impact of pulmonary tuberculosis on menstrual pattern and fertility. Clin Respir J 2010;4:157-61.
• [13] Kamper-Jorgensen Z, Lillebaek T, Andersen AB. Occupational tuberculosis following extremely short exposure. Clin Respir J 2009;3:55-7.
• [14] Türk Tabipleri Birliği Tüberküloz Raporu. Türk Tabipleri Birliği Yayınları. Birinci Baskı, Ocak 2012, Ankara.
• [15] Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis. 2009;49:1350-7.
• [16] Baumann MH, Nolan R, Petrini M, Lee YC, Light RW, Schneider E. Pleural tuberculosis in the United States: incidence and drug resistance. Chest 2007;131:1125-32.
• [17] Rowińska-Zakrzewska E, Korzeniewska-Koseła M, Roszkowski-Śliż K. Extrapulmonary tuberculosis in Poland in the years 1974-2010. Pneumonol Alergol Pol 2013;81:121-9.
• [18] Kulchavenya E. Extrapulmonary tuberculosis: are statistical reports accurate? Ther Adv Infect Dis 2014;2:61-70.
• [19] Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis (Seoul) 2015;78:47-55.
• [20] İnönü H, Köseoğlu D, Pazarlı C, Yılmaz A, Doruk S, Yenisehirli G, et al. [The characteristics of cases with extrapulmonary tuberculosis in a university hospital]. Tur Toraks Der 2010;11:167-73. [Article in Turkish]